Physician profile
Muhammad Asif
NPI 1043242654
$941.09
in general payments reported to CMS, 2019-2025
24 companies · $127 in 2025
The $127 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.99 · 2020: $78.78 · 2021: $145 · 2022: $86.30 · 2023: $273 · 2024: $192 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $135.32 | 2019-2023 | Xarelto |
| Vifor Pharma, INC. | $85.75 | 2020-2021 | |
| Novo Nordisk INC | $82.73 | 2020-2025 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.77 | 2022-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $61.94 | 2021-2024 | Farxiga |
| Gilead Sciences, INC. | $61.56 | 2022-2024 | Veklury |
| Pfizer INC. | $55.55 | 2019-2024 | |
| Vertex Pharmaceuticals Incorporated | $41.27 | 2025 | |
| Aimmune Therapeutics, INC. | $33.46 | 2024 | |
| Novartis Pharmaceuticals Corporation | $26.19 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.47 | 2021 | |
| Sk Life Science, INC. | $24.03 | 2020 | |
| Astellas Pharma US INC | $23.45 | 2023 | Cresemba |
| Alexion Pharmaceuticals, INC. | $23.22 | 2023 | Ultomiris |
| Exact Sciences Corporation | $23.13 | 2024 | Cologuard Collection Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $22.56 | 2023 | Xarelto |
| Ultragenyx Pharmaceutical INC. | $21.32 | 2023 | |
| Alnylam Pharmaceuticals INC. | $20.96 | 2023 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.63 | 2021 | |
| Boston Scientific Corporation | $17.88 | 2023 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $17.40 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $15.01 | 2024 | Sancuso |
| Amgen INC. | $14.47 | 2024 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $14.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Asif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.